|

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

RECRUITINGPhase 2Sponsored by Second Affiliated Hospital of Guangzhou Medical University
Actively Recruiting
PhasePhase 2
SponsorSecond Affiliated Hospital of Guangzhou Medical University
Started2021-01-01
Est. completion2029-01-01
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04803318

Summary

To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

Eligibility

Age: 18 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* Recurrent/Refractory advanced solid tumors
* Age between 18 and 85 years
* Expected life expectancy is greater than three months

Exclusion Criteria:

* Benign tumor
* Life expectancy is less than three months
* Serious medical commodities
* others

Conditions6

CancerHepatocellular CarcinomaLiver CancerLiver DiseaseLung CancerSolid Tumor, Adult

Browse More Trials

Cancer trialsLung Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.